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Is Contrast Material Needed after Treatment of 






Positron emission tomography (PET)/computed tomography (CT) with 
18
F-fluorodeoxyglucose (FDG) is widely used for post-therapeutic surveillance of 
malignant lymphoma. Debate still exists as to whether intravenous contrast media 
during the CT stage of a PET/CT scan should be used. The purpose of this study was to 
investigate the clinical value of contrast agent in PET/CT in patients with lymphoma 
following treatment. 
Patients and methods 
122 consecutive patients with malignant lymphoma underwent 146 PET/CT scans to 
monitor therapeutic response (n = 57) or surveillance during follow-up (n = 89). All 
patients had a conventional PET/CT scan with low-dose CT without contrast (ldCT), 
and then a full-dose CT scan with contrast (ceCT). Two datasets were interpreted 
separately and prevalence of discrepant results between the two methods was evaluated. 
In addition, differences of diagnostic performance were investigated for restaging. 
Results 
Both PET+ldCT and PET+ceCT were positive in 22 cases and negative in 35 cases 
3 
when monitoring response to therapy. There were no cases in which these techniques 
demonstrated inconsistent findings. For restaging, the patient-based sensitivity, 
specificity, positive predictive value, negative predictive value, and diagnostic accuracy 
of PET+ldCT were 70%, 91%, 76%, 87%, and 84%, respectively, and those of 
PET+ceCT were 74%, 92%, 81%, 89%, and 87%, respectively. Discrepant results 
between the two methods occurred in only 2 of 89 cases (2%). 
Conclusion 
PET/ceCT yielded more accurate findings than PET/ldCT in a limited number of cases. 
PET/ldCT may, therefore, be sufficient for routine PET/CT scanning for 
post-therapeutic assessment or restaging of lymphoma patients. 
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Introduction 
In the management of malignant lymphoma, diagnostic imaging is indispensable for 
creating an appropriate therapeutic strategy. Due to availability and low cost, computed 
tomography (CT) is the most commonly used imaging modality for evaluation of 
post-therapeutic condition, as well as initial staging before treatment. Iodine-based 
intravenous contrast material is often used during these scans to make interpretations 
more accurate and with confidence. However, it is difficult to evaluate the viability of 
lesions only by morphological information. 
Positron emission tomography (PET) using 
18
F-fluorodeoxyglucose (FDG) is a 
functional imaging tool, which detects viable lesions throughout the whole body. PET is 
thought to be useful for not only staging or restaging, but also for predicting prognosis 
of patients, especially after treatment [1,2]. PET can reflect biological status of the 
lesions earlier than morphological changes occur, which is useful in making decisions 
for therapeutic strategies. Although morphological changes have been traditionally used 
as an indicator of post-therapeutic status, it is currently recommended that PET findings, 
together with morphological findings, should be considered after chemotherapy and/or 
radiation therapy [3,4]. In order to overcome the lack of morphological information by 
PET, an inline PET-CT system has been developed, and metabolic information as well 
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as morphological status can be easily obtained at a single examination. This scanning 
method yields more findings that are accurate with higher confidence, as compared with 
CT alone or PET alone [5-7]. In addition, there has already been an article 
demonstrating that conventional contrast-enhanced CT might not be necessary when 
image fusion between PET and low-dose CT images is available using an inline 
PET/CT system [8]. 
A CT device, as a part of a combined PET/CT scanner, is a multidetector-row CT, 
which can be used as a standalone CT scanner in clinical situations. To reduce radiation 
exposure and cost, low-dose CT is usually adopted without intravenous contrast in 
conventional PET/CT scanning, which may cause limitations in image interpretation [9]. 
If full-dose CT scanning is performed with intravenous (IV) contrast, fused images 
between CT and PET may obtain more diagnostically valuable information to provide 
higher diagnostic accuracy. However, in monitoring or restaging after treatment in 
patients with lymphoma, systemic chemotherapy is under consideration for further 
therapeutic management. Therefore, unlike post-operative evaluation of colorectal 
cancer, it is not always necessary to detect each and every involved lesion, and 
patient-based evaluation is sufficient. However, whether low-dose unenhanced CT is 
sufficient after treatment or full-dose enhanced CT would be helpful to make 
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therapeutic decisions is still debatable. 
 The purpose of the current study was to compare the diagnostic performance between 
conventional PET/CT with low dose CT without contrast material (PET/ldCT) and 
PET/CT with full-dose CT and contrast enhancement (PET/ceCT). 
 
Patients and methods 
Patients 
 Between October 2007 and September 2008, 122 consecutive patients (69 males and 
53 females; mean age, 61 years; range, 18-89 years) with histologically proven 
malignant lymphoma underwent 146 PET/CT scans for monitoring therapy response (n 
= 57) or surveillance after treatment (n = 89). The patients' characteristics are 
summarized in Table 1. Patients gave written informed consent, as required in our 
institutional review board. 
 
PET/CT scanning 
 PET/CT scanning was performed using a combined PET/CT scanner (Discovery ST 
Elite-Performance, GE Healthcare). This system integrates a PET scanner with a 
multidetector-row CT (16 detectors), and permits the acquisition of coregistered CT and 
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PET images in a single examination. Patients fasted for at least 4 hours before 
administration of FDG. We checked patients' plasma glucose level just before injection 
of FDG, and there were no patients whose plasma gluose exceeded 150 mg/dl. The data 
acquisition started approximately 50 min after the injection of a standard dose of 200 - 
250 MBq of 
18
F-FDG. Initially, starting at the level of the thigh, the low-dose CT scans 
were acquired with the following parameters: 40 to 60 mA, 120 kV, 0.6-sec tube 
rotation, 3.75-mm section thickness. The CT scans were acquired during breath hold 
with the normal expiration position, and scanning included the area from the upper 
thigh to the skull base. Immediately after CT, a PET emission scan was acquired, with 
an acquisition time of 2 min per bed position. The total acquisition time was 
approximately 20 min. The CT data were used for attenuation correction, and images 
were reconstructed by using the 3-dimensional iterative reconstruction algorithm called 
VUE Point Plus. 
 Another CT scan with intravenous contrast material (Iopamiron Inj. Syringe, Bayer 
HealthCare), containing 300 or 370 mg/ml of iodine, was then performed, while the 
patient remained in the same position on the PET/CT table. We used the following 
parameters for CT scanning for diagnostic purpose: dose-modulated tube current up to 
350 mA; tube voltage 120 kV; pitch 1.35; 27.0 mm/rotation speed; contrast volume, 100 
ref #2-2 
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mL; injection rate 2.0 mL/sec; 100-sec delay. During full-dose CT with contrast, the 
patients remained in an unchanged supine position on the PET/CT, and scanning was 
performed during breath hold with the normal expiration position, similar to previous 
low-dose CT scanning. For image fusion, 3.75-mm slices were reconstructed. The 
low-dose CT without contrast, full-dose CT with contrast, and PET images were 
transferred to a commercially available workstation (Xeleris, GE Healthcare) in order to 
access all data. Oral CT contrast agent was not used in this investigation. 
 
Image evaluation 
 At least two board-certified radiologists and nuclear medicine physicians (YN and 
MN) interpreted the images. These physicians had 13 and 6 years experience, 
respectively, with PET, and 17 and 9 years experience, respectively, with CT. At first, 
using all clinical information available at the time of PET scan, the dataset of PET and 
low-dose CT images were reviewed and findings were obtained by consensus. Then, a 
dataset of PET and full-dose enhanced CT images were also interpreted. The diagnostic 
criteria was as follows: when PET showed focal moderate to intense uptake, compared 
to surrounding tissue, we regarded it as positive unless normal physiological uptake or 




showed mild to moderate uptake with corresponding morphological abnormalities on 
CT, we also considered it positive; and when PET showed equivocal uptake without 
morphological abnormality or PET showed no uptake with or without morphological 
abnormality on CT, we regarded it as negative. Quantitative analysis was not conducted 
in this investigation. 
 For monitoring after therapy, abnormal uptake indicating residual viable lesions was 
evaluated on patient-basis, and the difference of results was also assessed on 
region-basis. For restaging or follow-up, the sensitivity, specificity, and diagnostic 
accuracy were investigated on a patient-basis, based on clinical follow-up for at least 6 
months, excluding three patients who died of lymphoma within 100 days after scanning, 
and the difference of diagnostic accuracy was evaluated. In addition, the difference of 
results between the two methods was also assessed on a region-basis. 
 All the patients were analyzed and there were no patients who were excluded from the 
analysis. For 13 patients who had repeated scans for restaging or follow-up purpose, 
only the initial results were used for calculating diagnostic performance. 
 
Statistical analysis 




p<0.05 was considered statistically significant. 
 
Results 
For monitoring of response after treatment 
For monitoring after treatment, 48 patients had 57 PET/CT scans. Of these 57 scans, 
patient-based results were positive in 22 cases, and negative in 35 cases in both 
PET/ldCT and PET/ceCT. Table 2 demonstrates the number of patients for whom each 
interpretation method described lesions, which are classified by involved areas. There 
was no diagnostic discrepancy between the interpretation of PET/ldCT and PET/ceCT 
on a region basis, and positive findings in PET/ceCT were all interpreted as positive in 
PET/ldCT. 
 
For surveillance during follow-up 
For restaging or follow-up, 76 patients, including two patients who had had a PET/CT 
scan for monitoring after treatment before, received a PET/CT scan. Since 13 of 76 
patients had the PET/CT examination twice for this purpose, a total of 89 PET/CT scans 
were performed. Based on the final diagnoses, 23 patients were considered positive for 
relapse and 53 patients had no recurrence, with a prevalence rate of 30.3%. The number 
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of patients for whom each method described suspicious relapsed lesions is demonstrated 
in Table 3. Patient-based sensitivity, specificity, positive predictive value, negative 
predictive value and diagnostic accuracy of PET+ldCT were 70%, 91%, 76%, 87%, and 
84%, respectively, and those of PET+ceCT were 74%, 92%, 81%, 89%, and 87%, 
respectively. No statistically significant difference was found between the two scanning 
techniques, although discrepant results between the two methods occurred in 2 of 89 
cases (2%). A recurrent tumor in the pons was accurately diagnosed only by PET/ceCT 
in one case (Fig. 1), and intravenous thrombus was accurately diagnosed as negative 
involvement only by PET/ceCT in the other case (Fig. 2). In both interpretation methods, 
positive findings in four patients turned out to be false. Focal uptake in the left palatine 
tonsil, bilateral submandibular glands, mediastinal, and supraclavicular nodes were 
interpreted as positive for relapse, but they were unchanged or disappeared without any 
treatment on follow-up PET/CT. In addition, extranodal focal uptake in the right thigh 
was regarded as relapse in one patient, but decreased in size one month later due to 
antibiotic treatment, indicating inflammatory change. 
 
Discussion 
 In PET/CT examinations, our data shows that full-dose enhanced CT could be useful 
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for accurate diagnosis in a small number of specific cases, while low-dose unenhanced 
CT may be enough in most cases after treatment of malignant lymphoma. 
 As a combined PET/CT scanner has been installed in many institutes, an increasing 
number of reports describing the clinical usefulness of iodine-based contrast material 
for PET/CT scanning have occurred. For example, Soyka et al. demonstrated the 
superior diagnostic accuracy and therapeutic impact of PET/CT with contrast material 
and concluded that PET/ceCT may be considered as the first-line diagnostic tool for 
restaging in patients with colorectal cancer [10]. For patients who were suspected of 
having recurrent ovarian cancer or uterine cervical cancer, PET/CT with contrast 
material yielded the most accurate diagnostic performance [11,12]. 
As for malignant lymphoma, it is still debatable whether or not IV contrast should be 
used in evaluating disease status. In initial staging, Rodriguez-Vigil et al. compared the 
diagnostic performance of PET/ldCT and PET/ceCT, and found one case in which a 
splenic hilar lesion was correctly diagnosed only via PET/ceCT, resulting in more 
accurate staging. However, there was no statistically significant difference between the 
two methods [13]. In contrast, Morimoto et al. demonstrated that more diagnoses that 
are accurate were acquired by PET/ceCT for evaluating pelvic lesions in initial staging 
of lymphoma [14]. In addition, Vera et al. proposed that contrast enhanced PET/CT 
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without low-dose CT is recommended as a one-stop imaging test for monitoring or 
restaging. CT with contrast material can be applicable for attenuation correction with 
minimal influence for quantitative values of lesions, and excess radiation exposure can 
be avoided by omitting low-dose CT [15]. In our series, two cases were accurately 
diagnosed only by PET/ceCT, but both PET/ldCT and PET/ceCT brought consistent 
results in the majority of cases. These findings were similar to our previous 
investigation [16]. When information obtained via PET is available, there are no 
significant differences in diagnostic performance, whether fused images between PET 
and CT are read, PET and CT are interpreted side-by-side, or only PET images are read. 
In short, PET/ceCT is useful and yields the highest diagnostic accuracy, but PET/ldCT 
may be sufficient in most cases. Therefore, the use of intravenous contrast should be 
carefully considered for certain inconclusive cases to reduce medical cost. This strategy 
might also be useful to reduce adverse effects caused by iodine-based contrast material 
and to save medical cost without degrading diagnostic perfromance. 
In this population, there was one false negative case using PET/ldCT interpretation in 
patients who had a PET/CT scan for restaging. In the false negative case, positive 
involvement of the central nervous system (CNS) could only be diagnosed by 
PET/ceCT as one FDG-avid lesion was enhanced in the pons, which was confirmed by 
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MRI. It is well known that FDG accumulates in the brain, making it difficult to evaluate 
intracranial lesions. Therefore, if patients are suspected of having CNS involvement, the 
use of contrast material should be considered even in PET/CT studies. 
One false positive case occurred due to intravenous thrombus. It is known that FDG 
also accumulates in thrombus probably due to the infiltration of inflammatory cells, 
which can cause a false positive result in FDG-PET imaging [17,18]. This is a rarity, 
and accurate diagnosis was not obtained due to limited morphological information. In 
such a case, contrast material is helpful, but prior anticipation of accumulation in the 
thrombus may prove difficult, therefore the use of IV contrast should be considered 
when the possibility of uptake in the thrombus is suspected. 
There are certain limitations in this study. Strictly speaking, we did not compare the 
difference between PET/CT with contrast and PET/CT without contrast in this 
investigation, but compared between PET plus low-dose CT without contrast and PET 
plus full-dose CT with contrast. It would have been more appropriate to compare PET 
plus full-dose CT without contrast and PET plus full-dose CT with contrast in order to 
investigate the clinical value of IV contrast. However, the diagnostic performance of 
PET plus full-dose CT without contrast should be better than PET plus low-dose CT 
without contrast. As the diagnostic performance of PET plus low-dose CT without 
ref #2-5 
15 
contrast and PET plus full-dose CT with contrast was comparable, PET plus full-dose 
CT without contrast should have the same diagnostic ability. Furthermore, final 
diagnoses were obtained by clinical follow-up including imaging tests. 
Histopathological examination was not conducted due to an ethical issue; therefore 
sensitivity of the scanning methods may have been overestimated. Finally, no 
significant difference of sensitivity was observed between PET/ldCT and PET/ceCT, but 
it might be because the number of extra-nodal lesions was small in our population, i.e. 
five for monitoring therapy and eight for restaging or follow-up. As extra-nodal sites 
involved by lymphoma, stomach, bowel, liver, lung, and bone are representative organs. 
It is reported that PET/ceCT was more accurate and helpful for evaluating hepatic 
lesions, compared to PET/ldCT, although it was a study for liever metastasis from 
colorectal cancer [19]. According to our previous data, even extra-nodal lesions were 
accurately diagnosed by PET, not by CT with contrast [16], but further investigations 
with more cases of extra-nodal lesions is required to conclude that PET/ld CT would be 
sufficient for cases with extra-nodal lesions. 
 
Conclusions 




but cases where accurate diagnosis was obtained only via PET/ceCT were limited. For 
the purpose of monitoring therapy, the diagnostic performance was comparable between 
the two methods. IV contrast is not always necessary for post-therapeutic surveillance 
of malignant lymphoma when PET/CT is available, and should be considered only for 
use in certain undeterminable cases. 
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Table 1. Patients' characteristics.    
   
Male : Female 69 : 53  
   
Age (y)   
 Range 18 - 89  
 Mean 61  
   
Purpose of scanning   
 Monitoring therapeutic response 57  
 Restaging or follow-up 89  
   
Histopathology   
 Diffuse large B-cell lymphoma 63  
 Follicular lymphoma 17  
 Hodgkin lymphoma 8  
 Peripheral T-cell lymphoma 6  
 MALT lymphoma* 5  
 Extranodal NK/T-cell lymphoma, nasal type 4  
 Nodal marginal zone B-cell lymphoma 2  
 Mediastinal (thymic) large B-cell lymphoma 2  
 Angioimmunoblastic T-cell lymphoma 2  
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 Precursor T-lymphoblastic leukemia 2  
 Anaplastic large cell lymphoma 2  
 Burkitt’s lymphoma 1  
 Intravascular large B-cell lymphoma 1  
 Unknown 7  
   
Prior treatment   
 Chemotherapy 94  
 Chemoradiation therapy 21  
 Radiation therapy 4  
 Surgery and chemotherapy 2  
 Surgery only 1  
    
   
*:  Extranodal marginal zone B-cell lymphoma   
 
20 
Table 2. The number of patients for whom each method described the following involved areas. 
 
Area Cervical SC Axilla Med Paraaortic Iliac Inguinal Mesenteric Abd Ex-nodal 
PET+ldCT 9 3 3 5 5 4 3 9 4 5 
PET+ceCT 9 3 3 5 5 4 3 9 4 5 
 
Note. SC, Supraclavicular; Med, Mediastinal; Abd, Abdominal; Ex-nodal, Extra-nodal. 




Table 3. The Number of Patients for Whom Each Method Described the Following Involved Areas. 
 
Area Cervical SC Axilla Med Paraaortic Iliac Inguinal Mesenteric Abd Ex-nodal 
PET+ldCT 10 (2) 8 (1) 2 (0) 7 (1) 5 (0) 8 (1) 4 (0) 6 (0) 2 (0) 7 (1) 
PET+ceCT 10 (2) 8 (1) 2 (0) 7 (1) 5 (0) 7 (0) 4 (0) 6 (0) 2 (0) 8 (1) 
 
Note. SC, Supraclavicular; Med, Mediastinal; Abd, Abdominal; Ex-nodal, Extra-nodal. 
"Abd" included all abdominal nodal lesions except paraaortic, iliac or mesenteric nodes, e.g. hepatic hilar node. 
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An 81-year-old male with central nervous system involvement of recurrent malignant 
lymphoma. Axial slices of ldCT (A), fused image of ldCT with PET (B), PET (C), ceCT 
(D) and fused image of ceCT with PET (E) are demonstrated. A moderate uptake is 
observed in the posterior part of the pons (C: arrow), which was missed following 
interpretation of PET/ldCT scans. The accumulation corresponds to the enhanced mass 




A 44-year-old male who had been treated for anaplastic large cell lymphoma underwent 
a PET/CT scan for restaging. A coronal slice of ceCT (A), an axial slice of PET (B), 
ldCT (C), a fused image of ldCT with PET (D), ceCT (E), and a fused image of ceCT 
with PET (F) are demonstrated. A focal intense uptake was seen around the right iliac 
region (B: arrowhead), which was read as positive for relapse in interpreting PET/ldCT. 
Intravenous thrombus was demonstrated corresponding to the uptake by ceCT (A: 
27 
arrow), and the patient was treated with anticoagulant drugs. 


